79558-09-1
79558-09-1 结构式
基本信息
100877
L 1q5041
L-165,041
COMPOUND P
L-165041, >=98%
L165041
L 165041
L-165,041 - CAS 79558-09-1 - Calbiochem
2-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]-
4-[3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY)PROPOXY]PHENOXYACETIC ACID
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-20019 | L-165041 L-165041 | 79558-09-1 | 10mM * 1mLin DMSO | 664元 |
| 2024/04/30 | HY-20019 | L-165041 L-165041 | 79558-09-1 | 10mg | 884元 |
| 2024/04/30 | HY-20019 | L-165041 L-165041 | 79558-09-1 | 50mg | 3534元 |
常见问题列表
|
PPARδ 6 nM (Ki) |
PPARγ 730 nM (Ki) |
L-165041 is a PPARδ agonist, with K i s of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively. L-165041 (1 or 5 µM) inhibits VEGF-induced endothelial cells (ECs) proliferation and migration. L-165041 negatively affects cell cycle progression in VEGF-activated human umbilical vein ECs (HUVECs). L-165041 (10 µM)inhibits PPARδ-independent, VEGF-induced angiogenesis. PPARδ ligand L-165041 inhibits PDGF-induced rVSMC proliferation and migration. With 1 h of L-165041 pretreatment, PDGF-induced cellular migration is inhibited. L-165041 (10 μM) significantly suppresses S phase transition induced by PDGF.
L-165041 (5 mg/kg/day, i.p.) significantly lowers the formation of lipid droplets in mice. L-165041 markedly reduces the level of both the hepatic cholesterol and triglycerides in mice. L-165041 increases mRNA expression levels of PPARδ compared to the vehicle group. Lipoprotein lipase (LPL) expression in L-165041-treated mice is significantly higher than that in the vehicle group.